AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17970879 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. (LAC group) for 14 days
Number of subjects: 240
Study 15173777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole administration
Number of subjects: 18
Study 15173777 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched patients with normal perfusion and normal T1-201 lung uptake)
Number of subjects: 18
Study 11730781 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 0
Study 11730781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with artemether and praziquantel
Number of subjects: 0
Study 11730781 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 0
Study 9559241 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment programs
Number of subjects: 63
Study 7909912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg.kg‐1 body weight) administered intravenously after exercise
Number of subjects: 6
Study 7909912 — intervention group
Group type: COMPARATOR
Intervention: No beta‐adrenoceptor blocker administered
Number of subjects: 6
Study 7909912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administered during recovery from exercise
Number of subjects: 6
Study 2885802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (50 mg/kg/day divided in 2 doses for 10 days)
Number of subjects: 17
Study 2885802 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (21 patients)
Number of subjects: 17
Study 31852547 — intervention group
Group type: COMPARATOR
Intervention: Stepped-wedge cluster randomized trials (SW-CRTs) with delayed rollout of intervention
Number of subjects: 0
Study 31852547 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-CRTs
Number of subjects: 0
Study 28945992 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 U of cholecalciferol daily for 4 months
Number of subjects: 42
Study 28945992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25759545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/d orally
Number of subjects: 59
Study 25759545 — intervention group
Group type: COMPARATOR
Intervention: LAM plus ADV (LAM 100 mg/d orally + ADV 10 mg/d orally)
Number of subjects: 59
Study 23497779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 101
Study 23497779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 101
Study 21094030 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50mg per day) and sanchitongshu capsule (200mg three times a day)
Number of subjects: 140
Study 21094030 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (50mg per day) and placebo capsule
Number of subjects: 140
Study 19127598 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplements
Number of subjects: 0
Study 19127598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17455121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST: twice a week)
Number of subjects: 43
Study 17455121 — intervention group
Group type: COMPARATOR
Intervention: Continued Reduced Training (CRT: 3 ST sessions/2 weeks)
Number of subjects: 43
Study 14749647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone with concurrent low-dose oxytocin
Number of subjects: 151
Study 14749647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidosing of misoprostol (25 microg every 4 hours) followed by high-dose oxytocin
Number of subjects: 151
Study 14749647 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 151
Study 12197993 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef-containing (BC) diet, n = 10, 0.6 g protein.kg(‐1).d(‐1) from beef
Number of subjects: 21
Study 12197993 — intervention group
Group type: COMPARATOR
Intervention: Lactoovovegetarian (LOV) diet, n = 11, 0.6 g protein.kg(‐1).d(‐1) from textured vegetable protein (soy) sources
Number of subjects: 21
Study 12197993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LOV and BC)
Number of subjects: 21
Study 10220834 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-8 autoantibodies (IgG, IgM, IgA)
Number of subjects: 85
Study 10220834 — intervention group
Group type: EXPERIMENTAL
Intervention: High titers of anti-IL-8 antibody subclasses and complexes
Number of subjects: 85
Study 10220834 — intervention group
Group type: EXPERIMENTAL
Intervention: Free IgA and IgA/IL-8 complexes
Number of subjects: 85
Study 10220834 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgA subclass anti-IL-8 autoantibodies
Number of subjects: 85
Study 10220834 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-8 immune complexes
Number of subjects: 85
Study 8560312 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2203181 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg natamycin by nebuliser twice daily for one year
Number of subjects: 25
Study 2203181 — intervention group
Group type: COMPARATOR
Intervention: Placebo by nebuliser twice daily for one year
Number of subjects: 25
Study 359384 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 60
Study 359384 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole
Number of subjects: 60
Study 31923066 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fascial sling
Number of subjects: 924
Study 31923066 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 924
Study 31923066 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 924
Study 31923066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 924
Study 31923066 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 924
Study 30611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 80
Study 30611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (CDRI08)
Number of subjects: 80
Study 30611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 80
Study 30611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging techniques (Proton magnetic resonance spectroscopy, resting state functional connectivity, arterial spin labelled perfusion)
Number of subjects: 80
Study 30611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal samples analysis
Number of subjects: 80
Study 28425312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of PNU-120596 (8 µg/kg, 15 min before surgery)
Number of subjects: 0
Study 28425312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of PNU-120596
Number of subjects: 0
Study 28425312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of K+‐Cl‐ cotransporter‐2 inhibitor VU0240551
Number of subjects: 0
Study 25824475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) performed three times a week
Number of subjects: 30
Study 25824475 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (Control)
Number of subjects: 30
Study 23594421 — intervention group
Group type: EXPERIMENTAL
Intervention: New hearing aid
Number of subjects: 16
Study 23594421 — intervention group
Group type: COMPARATOR
Intervention: Conventional hearing aid
Number of subjects: 16
Study 21123030 — intervention group
Group type: COMPARATOR
Intervention: Dental maturation indices (Nolla and Demirjian)
Number of subjects: 155
Study 19657730 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga lifestyle intervention group (n = 15)
Number of subjects: 45
Study 19657730 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and meditation only group (n = 15)
Number of subjects: 45
Study 19657730 — intervention group
Group type: COMPARATOR
Intervention: No-practice control group (n = 15)
Number of subjects: 45
Study 17258587 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic side-biting clamp
Number of subjects: 42
Study 17258587 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclose II device
Number of subjects: 42
Study 17258587 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartstring II device
Number of subjects: 42
Study 15493396 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 grams taken twice on the day of dental treatment and 1 g taken twice the next day)
Number of subjects: 125
Study 15493396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15493396 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 125
Study 11189690 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control procedures for cancer screening tests (digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, flexible sigmoidoscopy)
Number of subjects: 0
Study 11189690 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance plan developed by PLCO quality assurance subcommittee
Number of subjects: 0
Study 11189690 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic data analyses
Number of subjects: 0
Study 11189690 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures for duplicating examinations
Number of subjects: 0
Study 9194104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil
Number of subjects: 364
Study 9194104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 364
Study 9194104 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime-proxetil or Amoxicillin-clavulanate
Number of subjects: 364
Study 1347336 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐CH (50 mg mitomycin intraoperatively)
Number of subjects: 50
Study 1347336 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticancer prophylaxis)
Number of subjects: 50
Study 1347336 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐CH
Number of subjects: 50
Study 3912787 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation therapy during a 3-week interval
Number of subjects: 8
Study 3912787 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment followed by progressive relaxation therapy
Number of subjects: 8
Study 31568636 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 10
Study 31568636 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control condition)
Number of subjects: 10
Study 31568636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 10
Study 31939369 — intervention group
Group type: EXPERIMENTAL
Intervention: Kedo‐S rotary file system
Number of subjects: 45
Study 31939369 — intervention group
Group type: EXPERIMENTAL
Intervention: K3 rotary file system
Number of subjects: 45
Study 31939369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand K‐file
Number of subjects: 45
Study 28902590 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 980
Study 28902590 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 980
Study 24233255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics enriched formula containing dietary oligosaccharides (scGOS/lcFOS) at a concentration of 0.8 g/100 ml
Number of subjects: 167
Study 24233255 — intervention group
Group type: COMPARATOR
Intervention: Common preterm formula
Number of subjects: 167
Study 22660441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (single dose)
Number of subjects: 24
Study 22660441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (daily for 30 days)
Number of subjects: 24
Study 21109025 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 712
Study 21109025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 20030830 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise tolerance testing followed by coronary angiography and treatment (percutaneous stenting or surgery) if positive results are found.
Number of subjects: 0
Study 20030830 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical/behavioral therapy offered to the exercise testing group.
Number of subjects: 0
Study 20030830 — intervention group
Group type: COMPARATOR
Intervention: Best medical/behavioral therapy offered to the control group (regular follow-up at diabetes outpatient services).
Number of subjects: 0
Study 17302724 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 240
Study 17302724 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 240
Study 17302724 — intervention group
Group type: COMPARATOR
Intervention: No pacing (control group)
Number of subjects: 240
Study 15010898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball approach speed of 1 m/s, 1.5 m/s, and 2 m/s with No-Goal impact requirement
Number of subjects: 0
Study 15010898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball approach speed with Near-Goal impact requirement
Number of subjects: 0
Study 15010898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball approach speed with Far-Goal impact requirement
Number of subjects: 0
Study 11401117 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 60
Study 11401117 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (GTN)
Number of subjects: 60
Study 9455667 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 227
Study 9455667 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment (segmental fusion)
Number of subjects: 227
Study 8399698 — intervention group
Group type: EXPERIMENTAL
Intervention: Request to explain refusal to participate
Number of subjects: 1240
Study 8399698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no request to explain refusal)
Number of subjects: 1240
Study 3533337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 30
Study 3533337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3533337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 30
Study 2646131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of enuresis alarm and 20 micrograms intranasal desmopressin
Number of subjects: 28
Study 2646131 — intervention group
Group type: COMPARATOR
Intervention: Alarm and placebo
Number of subjects: 28
Study 31654782 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 1633
Study 31654782 — intervention group
Group type: COMPARATOR
Intervention: No PMRT
Number of subjects: 1633
Study 31060540 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based physical education intervention programme supporting autonomy, competence, and relatedness
Number of subjects: 600
Study 31060540 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 600
Study 28372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (intrathecal 0.5% hyperbaric bupivacaine 12.5 mg and 25 μg fentanyl)
Number of subjects: 60
Study 28372680 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (intravenous analgesia, propofol, and rocuronium followed by endotracheal intubation)
Number of subjects: 60
Study 26148612 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 40
Study 26148612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23271674 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate empirical therapy with voriconazole
Number of subjects: 147
Study 23271674 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (placebo)
Number of subjects: 147
Study 21702936 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Infant-Toddler Social and Emotional Assessment (BITSEA)
Number of subjects: 31
Study 21702936 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 31
Study 17926205 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐anaesthetic gel
Number of subjects: 51
Study 17926205 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic gel (Instillagel)
Number of subjects: 51
Study 16935112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with CorCap cardiac support device
Number of subjects: 193
Study 16935112 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control)
Number of subjects: 193
Study 12632705 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 78‐item report card based on outpatient record audits
Number of subjects: 44
Study 12632705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no report cards)
Number of subjects: 44
Study 10683002 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (50 Gy in 5 weeks to the whole breast)
Number of subjects: 1010
Study 10683002 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 1010
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate 600 mg over 2 days and mefloquine 1,250 mg in divided doses
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether 640 mg over 2 days and mefloquine 1,250 mg in divided doses
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate alone 700 mg over 5 days
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether alone 800 mg over 5 days
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: quinine plus tetracycline for 7 days
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine 1,250 mg in divided doses
Number of subjects: 394
Study 9561593 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate 600 mg over 2 days and mefloquine 750 mg
Number of subjects: 394
Study 1529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg/day)
Number of subjects: 34
Study 1529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/day)
Number of subjects: 34
Study 3872627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg in a single intramuscular dose
Number of subjects: 54
Study 3872627 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 160 mg-800 mg of sulfamethoxazole orally twice daily for 7 days
Number of subjects: 54
Study 3872627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 54
Study 3872627 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 54
Study 29243408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 105
Study 29243408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide (ClO2)
Number of subjects: 105
Study 29243408 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3)
Number of subjects: 105
Study 29243408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF)
Number of subjects: 105
Study 29243408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF)
Number of subjects: 105
Study 29243408 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study 27788310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-increment group (olanzapine doubled to 20 mg/d or risperidone doubled to 6 mg/d)
Number of subjects: 103
Study 27788310 — intervention group
Group type: COMPARATOR
Intervention: Continuation group (olanzapine 10 mg/d or risperidone 3 mg/d)
Number of subjects: 103
Study 27788310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-increment group
Number of subjects: 103
Study 27788310 — intervention group
Group type: COMPARATOR
Intervention: Continuation group
Number of subjects: 103
Study 26688983 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine (extraction group, EG)
Number of subjects: 67
Study 26688983 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction (control group, CG)
Number of subjects: 67
Study 23365557 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily (EX10BID)
Number of subjects: 35
Study 23365557 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily (LIR1.2)
Number of subjects: 35
Study 23365557 — intervention group
Group type: COMPARATOR
Intervention: Placebo or active comparator
Number of subjects: 35
Study 20873080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at moderate intensity (60% of maximal effort) once a week for 12 weeks
Number of subjects: 37
Study 20873080 — intervention group
Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 37
Study 18955428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (Ai Chi and Halliwick methods)
Number of subjects: 25
Study 18955428 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (gym exercises)
Number of subjects: 25
Study 16193899 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy conservation course
Number of subjects: 169
Study 16193899 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 169
Study 11426917 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, Zafirlukast, Zileuton (antileukotriene agents)
Number of subjects: 0
Study 11426917 — intervention group
Group type: EXPERIMENTAL
Intervention: Antileukotriene agents in combination with low-dose or high-dose corticosteroids
Number of subjects: 0
Study 11426917 — intervention group
Group type: EXPERIMENTAL
Intervention: Antileukotriene agents
Number of subjects: 0
Study 9868650 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin, Ethambutol, and Clarithromycin
Number of subjects: 86
Study 9868650 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 86
Study 9868650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 86
Study 9868650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 86